Quarterly ResultAug 4, 2026, 07:33 AM
Harmony Biosciences Q2 Net Revenue $261.3M; Reiterates WAKIX Guidance
AI Summary
Harmony Biosciences reported strong Q2 2026 financial results, with WAKIX net revenue increasing 30% year-over-year to $261.3 million and estimated average patients growing to 8,950. The company reiterated its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion. Harmony also announced positive Phase 1 data for its orexin-2 receptor agonist BP-205, with Phase 1b and Phase 2 studies planned, and provided updates on other pipeline assets including Pitolisant GR and HD.
Key Highlights
- WAKIX net revenue grew 30% year-over-year to $261.3 million for Q2 2026.
- Estimated average WAKIX patients increased by 450 to 8,950 in Q2 2026.
- Reiterated 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
- Diluted earnings per share for Q2 2026 was $1.28, up from $0.68 in Q2 2025.
- Cash, cash equivalents, and investments totaled $962.5 million as of June 30, 2026.
- BP-205 Phase 1 SAD data demonstrated favorable pharmacokinetic and safety/tolerability profiles.
- Pitolisant GR NDA accepted by FDA with a target PDUFA date of April 1, 2027.
- Pitolisant HD Phase 3 topline data expected in 2027, with PDUFA in 2028.
Price Impact
More from HRMY